BeiGene’s Tislelizumab Receives NMPA’s Priority Review to sNDA for Urothelial Carcinoma in China
Shots: The sNDA follows clinical, non-clinical, chemistry, manufacturing and controls (CMC) data and P-II study results assessing Tislelizumab in 113 patients with LA
[Read More...]
